Literature DB >> 8943478

Enhanced production of glomerular extracellular matrix in a new mouse strain of high serum IgA ddY mice.

E Muso1, H Yoshida, E Takeuchi, M Yashiro, H Matsushima, A Oyama, K Suyama, T Kawamura, T Kamata, S Miyawaki, S Izui, S Sasayama.   

Abstract

To investigate the relationship between high serum levels of IgA and glomerular lesions, selective mating was performed in high serum IgA ddY mice, a murine model of spontaneously developing mesangioproliferative glomerulonephritis mimicking human IgA nephropathy. The selection and mating of high IgA ddY mice were accomplished when the mice were three to four months old. In the 12th generation of high IgA ddY (HIGA) mice, significantly higher levels of serum IgA from 10 age weeks to 60 weeks (P < 0.0002 to 0.0001) were observed in comparison with BALB/c mice. Relatively high proteinuria was observed at 40 weeks of age, although hematuria was consistently negative. Microscopic observations of renal tissue disclosed a marked glomerular mesangial matrix increase and a reduction of cell proliferation with age by both semiquantitative and morphometric analyses with moderate tubulointerstitial damage. These mesangial matrices were stained markedly by antisera for collagen type IV and by fibronectin, but not by collagen type I. Localization of TGF-beta protein was also detected in the mesangium of the HIGA mice. The positive mesangial IgA deposition was maintained consistently by this mating procedure and became more marked with age. Size analysis of IgA from ten pooled HIGA mice aged 50 to 60 weeks revealed dominant polymeric IgA in sera and dimeric IgA in glomerular eluates. Clonal analysis of serum IgA disclosed heterogeneous spectrotypes in a wide pH range (4.5 to 6.5), in contrast to very limited spectrotypes in the acidic pH range (4.5 to 5.2) of IgA in the glomerular eluates from these mice. The analyses of retroviral gp70 antigen involvement in the HIGA mice disclosed a significant increase of serum levels of gp70 anti-gp70 immune complexes with age, with no relationship to the severity of glomerular gp70 deposition. Northern blot analysis of renal tissue revealed markedly high mRNA expression of collagen type I, IV, fibronectin and TGF-beta even in 10-week-old HIGA mice in comparison with BALB/c mice. The expression became more significant in 60-week-old animals. The genetic background required to induce the expansion of IgA-producing B-cell clones is suggested to be closely related to the increased gene expression of TGF-beta, which induces enhanced glomerular extracellular matrix (especially fibronectin) accumulation in HIGA mice, being possibly mediated by the mesangial deposition of dimeric and highly acidic IgA. This newly established strain may provide a model for investigating the relationship between progressive glomerular sclerotic lesions and the induction of pathogenic IgA in human IgA nephropathy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943478     DOI: 10.1038/ki.1996.517

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  15 in total

1.  Development of Animal Models of Human IgA Nephropathy.

Authors:  Hitoshi Suzuki; Yusuke Suzuki; Jan Novak; Yasuhiko Tomino
Journal:  Drug Discov Today Dis Models       Date:  2014

2.  (E)-N-[(3,4-dimethoxyphenethyl)]-N-methyl-3-(3-pyridyl)-2-propenamide (TJN-331) inhibits mesangial expansion in experimental IgA nephropathy in ddY mice.

Authors:  Yayoi Saegusa; Chiharu Sadakane; Junichi Koseki; Yoshihiro Hasegawa; Shoichiro Shindo; Shuichi Takeda; Hiroshi Takeda; Tomohisa Hattori
Journal:  Clin Exp Nephrol       Date:  2010-09-04       Impact factor: 2.801

3.  CD16+CD56+ cells are a potential culprit for hematuria in IgA nephropathy.

Authors:  Hirotsugu Iwatani; Yasuyuki Nagasawa; Ryohei Yamamoto; Kenichiro Iio; Masayuki Mizui; Arata Horii; Tadashi Kitahara; Hidenori Inohara; Atsushi Kumanogoh; Enyu Imai; Hiromi Rakugi; Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2014-05-06       Impact factor: 2.801

4.  Role of activated intrarenal reactive oxygen species and renin-angiotensin system in IgA nephropathy model mice.

Authors:  Naro Ohashi; Akemi Katsurada; Kayoko Miyata; Ryousuke Satou; Toshie Saito; Maki Urushihara; Hiroyuki Kobori
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-03-02       Impact factor: 2.557

5.  Activation of reactive oxygen species and the renin-angiotensin system in IgA nephropathy model mice.

Authors:  Naro Ohashi; Akemi Katsurada; Kayoko Miyata; Ryousuke Satou; Toshie Saito; Maki Urushihara; Hiroyuki Kobori
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-10-28       Impact factor: 2.557

Review 6.  Activated intrarenal reactive oxygen species and renin angiotensin system in IgA nephropathy.

Authors:  N Ohashi; M Urushihara; H Kobori
Journal:  Minerva Urol Nefrol       Date:  2009-03       Impact factor: 3.720

7.  Long-term follow-up of patients with IgA nephropathy treated with prednisolone and cyclophosphamide therapy.

Authors:  Satoshi Oshima; Osamu Kawamura
Journal:  Clin Exp Nephrol       Date:  2008-03-08       Impact factor: 2.801

8.  Development of a model of early-onset IgA nephropathy.

Authors:  Keiko Okazaki; Yusuke Suzuki; Mareki Otsuji; Hitoshi Suzuki; Masao Kihara; Tadahiro Kajiyama; Azusa Hashimoto; Hiroyuki Nishimura; Rhubell Brown; Stacy Hall; Jan Novak; Shozo Izui; Sachiko Hirose; Yasuhiko Tomino
Journal:  J Am Soc Nephrol       Date:  2012-07-12       Impact factor: 10.121

9.  Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice.

Authors:  P Launay; B Grossetête; M Arcos-Fajardo; E Gaudin; S P Torres; L Beaudoin; N Patey-Mariaud de Serre; A Lehuen; R C Monteiro
Journal:  J Exp Med       Date:  2000-06-05       Impact factor: 14.307

Review 10.  Are there animal models of IgA nephropathy?

Authors:  Renato C Monteiro; Yusuke Suzuki
Journal:  Semin Immunopathol       Date:  2021-07-07       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.